These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10595370)

  • 1. Selective degradation of targeted mRNAs using partially modified oligonucleotides.
    Dagle JM; Weeks DL
    Methods Enzymol; 2000; 313():420-36. PubMed ID: 10595370
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted degradation of mRNA in Xenopus oocytes and embryos directed by modified oligonucleotides: studies of An2 and cyclin in embryogenesis.
    Dagle JM; Walder JA; Weeks DL
    Nucleic Acids Res; 1990 Aug; 18(16):4751-7. PubMed ID: 1697675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotides selected by hybridisation to scanning arrays are effective reagents in vivo.
    Sohail M; Hochegger H; Klotzbücher A; Guellec RL; Hunt T; Southern EM
    Nucleic Acids Res; 2001 May; 29(10):2041-51. PubMed ID: 11353073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted elimination of zygotic messages in Xenopus laevis embryos by modified oligonucleotides possessing terminal cationic linkages.
    Dagle JM; Littig JL; Sutherland LB; Weeks DL
    Nucleic Acids Res; 2000 May; 28(10):2153-7. PubMed ID: 10773085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathways of degradation and mechanism of action of antisense oligonucleotides in Xenopus laevis embryos.
    Dagle JM; Weeks DL; Walder JA
    Antisense Res Dev; 1991; 1(1):11-20. PubMed ID: 1668307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric oligodeoxynucleotide analogs: chemical synthesis, purification, and molecular and cellular biology protocols.
    Giles RV; Spiller DG; Tidd DM
    Methods Enzymol; 2000; 313():95-135. PubMed ID: 10595351
    [No Abstract]   [Full Text] [Related]  

  • 7. Inactivation of gene expression using ribonuclease P and external guide sequences.
    Guerrier-Takada C; Altman S
    Methods Enzymol; 2000; 313():442-56. PubMed ID: 10595372
    [No Abstract]   [Full Text] [Related]  

  • 8. Rational selection of antisense oligonucleotide sequences.
    Smith L; Andersen KB; Hovgaard L; Jaroszewski JW
    Eur J Pharm Sci; 2000 Sep; 11(3):191-8. PubMed ID: 11042224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene switching: analyzing a broad range of mutations using steric block antisense oligonucleotides.
    Morcos PA
    Methods Enzymol; 2000; 313():174-89. PubMed ID: 10595356
    [No Abstract]   [Full Text] [Related]  

  • 10. CPEB, maskin, and cyclin B1 mRNA at the mitotic apparatus: implications for local translational control of cell division.
    Groisman I; Huang YS; Mendez R; Cao Q; Theurkauf W; Richter JD
    Cell; 2000 Oct; 103(3):435-47. PubMed ID: 11081630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression.
    Uhlmann E; Peyman A; Ryte A; Schmidt A; Buddecke E
    Methods Enzymol; 2000; 313():268-84. PubMed ID: 10595361
    [No Abstract]   [Full Text] [Related]  

  • 12. Selective elimination of mRNAs in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity.
    Dash P; Lotan I; Knapp M; Kandel ER; Goelet P
    Proc Natl Acad Sci U S A; 1987 Nov; 84(22):7896-900. PubMed ID: 2825169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense knockdown of cyclin E does not affect the midblastula transition in Xenopus laevis embryos.
    Slevin MK; Lyons-Levy G; Weeks DL; Hartley RS
    Cell Cycle; 2005 Oct; 4(10):1396-402. PubMed ID: 16131839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New candidates for true antisense.
    Toulmé JJ
    Nat Biotechnol; 2001 Jan; 19(1):17-8. PubMed ID: 11135542
    [No Abstract]   [Full Text] [Related]  

  • 15. Basic principles of using antisense oligonucleotides in vivo.
    Phillips MI; Zhang YC
    Methods Enzymol; 2000; 313():46-56. PubMed ID: 10595348
    [No Abstract]   [Full Text] [Related]  

  • 16. Translational control of cyclin B1 mRNA during meiotic maturation: coordinated repression and cytoplasmic polyadenylation.
    Barkoff AF; Dickson KS; Gray NK; Wickens M
    Dev Biol; 2000 Apr; 220(1):97-109. PubMed ID: 10720434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A more efficient and specific strategy in the ablation of mRNA in Xenopus laevis using mixtures of antisense oligos.
    Morgan R; Edge M; Colman A
    Nucleic Acids Res; 1993 Sep; 21(19):4615-20. PubMed ID: 8233799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of antisense and triplex-forming oligonucleotides.
    François JC; Lacoste J; Lacroix L; Mergny JL
    Methods Enzymol; 2000; 313():74-95. PubMed ID: 10595350
    [No Abstract]   [Full Text] [Related]  

  • 19. Expression of cyclin B1 messenger RNA isoforms and initiation of cytoplasmic polyadenylation in the bovine oocyte.
    Tremblay K; Vigneault C; McGraw S; Sirard MA
    Biol Reprod; 2005 Apr; 72(4):1037-44. PubMed ID: 15601923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible depletion of specific RNAs by antisense oligodeoxynucleotide-targeted degradation in frog oocytes.
    Eliceiri GL
    Methods Enzymol; 2000; 313():436-42. PubMed ID: 10595371
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.